AstraZeneca in Talks with Gilead for a Megamerger

 AstraZeneca in Talks with Gilead for a Megamerger

AstraZeneca in Talks with Gilead for a Megamerger

Shots:

  • As per Bloomberg, AstraZeneca communicated with Gilead about a possible merger to form the world’s largest drug company. Last month, AstraZeneca approached Gilead to measure its interest in a possible merger
  • The merger would unite two of the companies at the forefront of the industry’s efforts to combat COVID-19 and could be politically sensitive as governments seek control over potential vaccines or treatments
  • If combined, the two companies would have a market capitalization of ~$232B, which would surpass Merck & Co. and Pfizer at $207B and $200B respectively. Additionally, the deal would exceed BMS’ $74B acquisition of Celgene

Click here to read full press release/ article | Ref: Bloomberg | Image: Bloomberg

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post